-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Utidelone in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Utidelone in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Utidelone in Gastric Cancer Drug Details: Utidelone is an microtubule stabilizing...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Utidelone in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Utidelone in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Utidelone in Solid Tumor Drug Details: Utidelone is an microtubule stabilizing...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Utidelone in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Utidelone in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Utidelone in Triple-Negative Breast Cancer (TNBC) Drug Details: Utidelone...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Utidelone in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Utidelone in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Utidelone...
-
Sector Analysis
Cell and Gene Therapies in CNS Disorders – Disease Overview, Treatment Options and Future Market Assessment
Reasons to buy the ‘Cell and Gene Therapies in CNS Disorders’ report: The report covers the global scope of drug development focusing mainly on the 8MM including the US, 5EU, Japan, and South Korea. The report focuses on the marketed CGT assets addressing CNS disorders as well as the top five CNS disorders with the most CGT pipeline assets. The report throws light on the competitive landscape of leading CGT agents in CNS Disorders including launch date projections, analyst consensus...
-
Product Insights
NewMuscle Atrophy – Drugs In Development, 2024
Empower your strategies with our Muscle Atrophy – Drugs In Development, 2024 report and make more profitable business decisions. Muscle atrophy is the wasting or loss of muscle tissue. Symptoms of muscle atrophy include muscle damage, pain, weak muscles, loss of movement, facial weakness, and numbness or tingling in arms or legs. Causes include aging, nerve diseases, stroke, motor neuropathy, muscular dystrophy, and arthritis. Treatment includes exercise, dietary changes, and surgery. The Muscle Atrophy drugs in development market research report provide...
-
Product Insights
NewThromboangiitis obliterans (Buerger disease) – Drugs In Development, 2024
Empower your strategies with our Thromboangiitis obliterans (Buerger disease) – Drugs In Development, 2024 report and make more profitable business decisions. Thromboangiitis obliterans (TAO), also called Buerger disease, is a rare nonatherosclerotic inflammatory disorder in which blood vessels of the hands and feet become blocked. It has a strong association with smoking. Symptoms of Buerger’s disease are hand or foot pain (burning or tingling feeling), sores on toes or fingers, change in skin color or texture, and cold hands or feet....
-
Product Insights
NewVasculitis – Drugs In Development, 2024
Empower your strategies with our Vasculitis – Drugs In Development, 2024 report and make more profitable business decisions. Vasculitis is a term that refers to a group of diseases that cause inflammation of the blood vessels, affecting both arteries and veins. Vasculitis can have various causes, such as genetic factors, infections, immune system disorders, blood cancers, or reactions to certain drugs. Vasculitis can affect different parts of the body, such as the skin, muscles, joints, nerves, lungs, heart, digestive system, kidneys,...
-
Product Insights
NewSpinal Cord Injury – Drugs In Development, 2024
Empower your strategies with our Spinal Cord Injury – Drugs In Development, 2024 report and make more profitable business decisions. Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida, or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head, or...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GH-55 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GH-55 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GH-55 in Solid Tumor Drug Details: GH-55 is under development for...